Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

DanDrit Biotech USA

DanDrit Biotech USA
2001 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
ENOB STOCK SYMBOL
$5.25 SHARE PRICE (As of Tuesday Closing)
Description

Developer of the world's first vaccine against colorectal cancer. The company's business focuses on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer.

Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
  • 375 Park Avenue
  • Suite 2607
  • New York, NY 10152
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore DanDrit Biotech USA’s full profile, request a free trial.

DanDrit Biotech USA Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.25 - $6.85 $195M $5.39 -$0.09 10.8K 13.9M

DanDrit Biotech USA Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
30-Jun-2017
FY 2016
30-Jun-2016
FY 2015
30-Jun-2015
Enterprise Value 63,109 21,771 23,913 59,263
Revenue 0 43
EBITDA (2,167) (2,168) (3,028)
Net Income (2,143) (1,735) (2,673)
Total Assets 7,827 4,522 871 2,073
Total Debt 209 2,090 103 101
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DanDrit Biotech USA Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore DanDrit Biotech USA‘s full profile, request access.

Request full access to PitchBook

DanDrit Biotech USA Executive Team (1)

Name Title Board
Seat
Contact
Info
Eric Leire MD Chief Executive Officer & Director